COH29 is an orally bioavailable thiazole derivative that acts as a ribonucleotide reductase (RNR) inhibitor, targeting the hRRM2 subunit to deplete dNTP pools and impair DNA synthesis. It has demonstrated antineoplastic activity in vitro and in vivo, showing potential in cancer research, particularly in studies involving DNA replication stress and PARP1 inhibition.